Ind-Swift Laboratories Limited
Incorporated in 1995, Ind-Swift Laboratories Ltd is in the business of Bulk Drugs & Pharmaceuticals
What Ind-Swift files
- Others65
- Important25
- Updates24
- Board Meeting13
- Insider Trade6
- QIP/Rights/Pref.6
Ind-Swift Laboratories' Preferential Issue Committee approved the issue price for warrants at Rs. 196 each, above the Rs. 195.98 minimum determined by valuation. This preferential allotment will raise capital for the company.
Ind-Swift Labs responded to unusual stock volume/price activity, stating no specific company reason. Management attributes the surge to market forces and prevailing conditions.
Ind-Swift is upgrading its Jammu plant to EU-GMP/PICS standards, targeting ₹100 Cr additional revenue. This ₹45 Cr investment aims to expand into European export markets. The company also saw strong quarterly operating income and PAT growth.
Ind-Swift Labs' committee approved a revised EGM notice for a preferential issue of fully convertible warrants. This clarifies details after stock exchange queries, paving the way for a potential capital raise.
Company updated its code for trading by insiders to enhance fair disclosure and prevent misuse of price-sensitive info. Designated persons must report trades exceeding ₹0.1 Cr, reinforcing compliance.